Abstract
Heptapeptide, including seven amino acids of the PKCδ V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin (Kim et al., 2007), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 284-290 |
| Number of pages | 7 |
| Journal | Drug and Chemical Toxicology |
| Volume | 33 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2010 |
Bibliographical note
Funding Information:This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare, and Family Affairs (A080997) and by a grant from the Nuclear Research and Development Program of the National Research Foundation of the Ministry for Education, Science, and Technology (grant code: M2AMA006) of the Korean government. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Heptapeptide
- HSP27
- PCKδ
- Safety
- Toxicology
Fingerprint
Dive into the research topics of 'Repeated-dose toxicity of HSP27-binding heptapeptide in mice'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver